Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Influenza

Free Subscription 27.04.2026 3 Ann Intern Med 1 Biochemistry 1 J Infect 6 J Virol 1 MMWR Morb Mortal Wkly Rep 1 N Engl J Med 1 Pediatrics 2 PLoS Comput Biol 11 PLoS One 1 Proc Natl Acad Sci U S A 11 Vaccine

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Intern Med

1. LIM SY, Lee J, Chang E, Kwon JS, et al
   Neither Metformin nor Ursodeoxycholic Acid Effectively Treats Postacute Sequelae of COVID-19 : A Randomized Clinical Trial.
   Ann Intern Med. 2026 Mar 3. doi: 10.7326/ANNALS-25-04883.
   PubMed         Abstract available
   
   
2. QASEEM A, Obley AJ, Yost J, Abraham GM, et al
   Outpatient Treatment of Confirmed COVID-19 in Symptomatic Adults: Living, Rapid Practice Points From the American College of Physicians (Version 3).
   Ann Intern Med. 2026 Feb 10. doi: 10.7326/ANNALS-25-03766.
   PubMed         Abstract available
   
   
3. SOMMER I, Dobrescu A, Gadinger A, Sharifan A, et al
   Outpatient Treatment of Confirmed COVID-19: A Living, Rapid Review for the American College of Physicians (Version 3).
   Ann Intern Med. 2026 Feb 10. doi: 10.7326/ANNALS-25-03691.
   PubMed         Abstract available
   
   

   
   Biochemistry

4. MEDEIROS-SILVA J, Zhang Y, Hong M
   Phosphatidylinositol Interactions with the SARS-CoV-2 Envelope Protein Investigated by Lipid (13)C Labeling and Solid-State NMR.
   Biochemistry. 2026;65:1178-1191.
   PubMed         Abstract available
   
   

   
   J Infect

5. COX SN, Bennett JC, Casto AM, Hoffman KL, et al
   INFLUENZA HOUSEHOLD TRANSMISSION AND GENOMIC DIVERSITY IN THE UNITED STATES: A PROSPECTIVE COHORT STUDY, 2022-2024.
   J Infect. 2026 Apr 20:106748. doi: 10.1016/j.jinf.2026.106748.
   PubMed         Abstract available
   
   

   
   J Virol

6. ZHANG R, Jian X, Zhang Y, Sun Y, et al
   The oral nucleoside analogue inhibitor VV251 effectively inhibits coinfection by respiratory syncytial virus and influenza A virus.
   J Virol. 2026 Apr 21:e0000626. doi: 10.1128/jvi.00006.
   PubMed         Abstract available
   
   
7. YILDIZ S, El Zahed SS, Villalon-Letelier F, Wang Q, et al
   Re-engineering segment 8 facilitates generation of a versatile live-attenuated influenza A virus vector platform for secretory protein delivery.
   J Virol. 2026 Apr 21:e0034726. doi: 10.1128/jvi.00347.
   PubMed         Abstract available
   
   
8. KONG W, Zhang J, Song Y, Song J, et al
   Disruption of spike protein N-glycosylation induces its endoplasmic reticulum retention and attenuates SARS-CoV-2 infectivity.
   J Virol. 2026 Mar 30:e0027026. doi: 10.1128/jvi.00270.
   PubMed         Abstract available
   
   
9. XIU R, Wang Y, Cai W, Wang Q, et al
   Potent in vitro synergistic antiviral effects of the pan-coronavirus fusion inhibitor EK1 in combination with RBD-specific antibodies or M(pro) inhibitors.
   J Virol. 2026 Mar 30:e0007626. doi: 10.1128/jvi.00076.
   PubMed         Abstract available
   
   
10. BRENNAN JW, Wang G, Connor S, Wang X, et al
    A respiratory syncytial virus trailer sequence modulates viral replication and the generation and propagation kinetics of copy-back defective viral genomes.
    J Virol. 2026;100:e0018426.
    PubMed         Abstract available
    
    
11. ADAM A, Wu W, Jones MC, Hao H, et al
    Respiratory syncytial virus infection induces heterologous protection against SARS-CoV-2 through gammadelta T cell-mediated trained immunity and the activation of SARS-CoV-2-reactive mucosal T cells.
    J Virol. 2026 Mar 18:e0165825. doi: 10.1128/jvi.01658.
    PubMed         Abstract available
    
    

    
    MMWR Morb Mortal Wkly Rep

12. BELL JM, Barbre K, Meng L, Lape-Newman B, et al
    Influenza Vaccination Coverage Among Nursing Home Residents and Health Care Personnel - United States, 2024-25 Influenza Season.
    MMWR Morb Mortal Wkly Rep. 2026;75:195-201.
    PubMed         Abstract available
    
    

    
    N Engl J Med

13. BUTLER CC, Pinto AD, Harris V, Holmes J, et al
    Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients.
    N Engl J Med. 2026;394:1583-1594.
    PubMed         Abstract available
    
    

    
    Pediatrics

14. SEGEV N, Wilson E, Moehlman M, Corathers SD, et al
    Unmasking Adrenal Insufficiency: Adrenal Crisis Triggered by Influenza-Associated Encephalitis.
    Pediatrics. 2026 Apr 22:e2025072983. doi: 10.1542/peds.2025-072983.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

15. LI Y, Nielsen BF, Levin SA, Te Velthuis AJW, et al
    Spatio-temporal modelling of in vitro influenza A virus infection: The impact of defective interfering particles on the type I interferon response.
    PLoS Comput Biol. 2026;22:e1014198.
    PubMed         Abstract available
    
    
16. WHITE LA, Leon TM
    Forecastability of infectious disease time series: are some seasons and pathogens intrinsically more difficult to forecast?
    PLoS Comput Biol. 2026;22:e1014175.
    PubMed         Abstract available
    
    

    
    PLoS One

17. ORTEGA-MARTIN E, Alvarez-Galvez J
    Understanding quality-of-life patterns in long COVID: How Symptoms and socioeconomic conditions shape patient wellbeing.
    PLoS One. 2026;21:e0347743.
    PubMed         Abstract available
    
    
18. CHAVES SS, Castells VB, Mira-Iglesias A, Puig-Barbera J, et al
    Rhinovirus/enterovirus contribution to respiratory-associated hospitalizations in adults during respiratory seasons in Spain: A 6-year prospective study.
    PLoS One. 2026;21:e0347659.
    PubMed         Abstract available
    
    
19. LEE J, Bajiya VP, Jung E
    Vaccination scenario-based study on seasonal influenza in Republic of Korea.
    PLoS One. 2026;21:e0322686.
    PubMed         Abstract available
    
    
20. PIRZADA P, Wilde A, Doherty GH, Harris-Birtill D, et al
    Understanding older adults' perception, acceptance, and adoption of smart home technologies.
    PLoS One. 2026;21:e0345563.
    PubMed         Abstract available
    
    
21. FANG Z, Xu H, Mu Y
    Risk-taking responses to crash experience: Evidence from China.
    PLoS One. 2026;21:e0347543.
    PubMed         Abstract available
    
    
22. GARZA J, Sebastian R, Cover B, Sanchez A, et al
    Nicotine dependence among critically ill COVID-19 patients: A population-based cohort study.
    PLoS One. 2026;21:e0308776.
    PubMed         Abstract available
    
    
23. MCDONALD C, Grajales AG, Yahia NA, Fisman D, et al
    Healthcare resource utilization and cost burden of COVID-19 according to vaccination status in adults in Ontario, Canada, 2021-2023.
    PLoS One. 2026;21:e0344690.
    PubMed         Abstract available
    
    
24. LOVATO N, Appleton SL, Reynolds AC, Gill TK, et al
    Relationships between pre-pandemic mental health, sociodemographic factors and health behaviours in older adults during the acute onset of COVID-19 in Australia: A descriptive analysis.
    PLoS One. 2026;21:e0346787.
    PubMed         Abstract available
    
    
25. AUDUREAU E, Jean C, Layese R, Neuraz A, et al
    Association between parenthood and survival among 30,386 patients hospitalized with COVID-19.
    PLoS One. 2026;21:e0346679.
    PubMed         Abstract available
    
    
26. IPEKCI AM, Hodel EM, Filsinger M, Wegmuller S, et al
    Who would take part in a pandemic preparedness cohort study? The role of vaccine-related affective polarisation: Cross-sectional survey.
    PLoS One. 2026;21:e0346420.
    PubMed         Abstract available
    
    
27. YANG Z, Imouza A, Puelma Touzel M, Amadoro C, et al
    Regional and temporal patterns of partisan polarization during the COVID-19 pandemic in the United States and Canada.
    PLoS One. 2026;21:e0347327.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

28. SANDERS CG, Liu M, Fusco JA, Ohl EM, et al
    Efficient replication of influenza D virus in the human airway underscores zoonotic potential.
    Proc Natl Acad Sci U S A. 2026;123:e2530325123.
    PubMed         Abstract available
    
    

    
    Vaccine

29. ROBERTSON AH, Wolf AS, Fossum E, Solum G, et al
    Long-lasting cross-reactive and polyfunctional SARS-CoV-2 T cell responses in seniors are maintained after repeated vaccination and infections.
    Vaccine. 2026;80:128511.
    PubMed         Abstract available
    
    
30. DLOUHY P, Petras M, Lesna IK, Macalik R, et al
    Transient elevation of NT-proBNP after mRNA COVID-19 vaccination in healthy adults: A longitudinal biomarker analysis.
    Vaccine. 2026;80:128535.
    PubMed         Abstract available
    
    
31. VAN DE BURGWAL LHM, Pronker ES, Herz J
    Australia's vaccine legacy: Time for a boost? Mapping an innovation system in a fragmented data environment.
    Vaccine. 2026;80:128525.
    PubMed         Abstract available
    
    
32. WU D, Liu K
    Cost and effectiveness of COVID-19 vaccination strategies during the 2023 post-reopening omicron wave in Xinjiang, Western China: Evidence from SIR and Markov models.
    Vaccine. 2026;80:128536.
    PubMed         Abstract available
    
    
33. MAEDA H, Saito N, Igarashi A, Ishida M, et al
    Effectiveness of JN.1-adapted COVID-19 vaccine against medically attended SARS-CoV-2 infection and COVID-19 hospitalization in adults in Japan, from October 2024 to April 2025: VERSUS.
    Vaccine. 2026;80:128544.
    PubMed         Abstract available
    
    
34. MORO PL, Romanson B, Marquez P, Zhang B, et al
    Adverse events after Pfizer's Respiratory Syncytial Virus Vaccine in pregnant women in the Vaccine Adverse Event Reporting System, 2024-2025, United States.
    Vaccine. 2026;80:128547.
    PubMed         Abstract available
    
    
35. QUINTANAR-SOLARES M, Fleming JA, Musau W, Mulati F, et al
    RSV ready? Exploring feasibility and acceptability of RSV immunization options in low- and middle-income countries.
    Vaccine. 2026;80:128550.
    PubMed         Abstract available
    
    
36. KITANO T, Hashimoto E, Sado T, Yoshida S, et al
    Maternal effectiveness of respiratory syncytial virus using multicenter healthcare records: A retrospective cohort study.
    Vaccine. 2026;80:128566.
    PubMed         Abstract available
    
    
37. ZHANG L, Lin T, Wang M, Ma X, et al
    Effectiveness of prescription-based influenza vaccination services among older adults in Binzhou, China: A cluster-randomized controlled trial.
    Vaccine. 2026;82:128588.
    PubMed         Abstract available
    
    
38. FOLEGATTI PM, Pepin S, Tabar C, Fries K, et al
    Immunogenicity and safety of recombinant influenza vaccine versus standard inactivated influenza vaccine in children aged 3 to 8 years: results from a phase III randomised study.
    Vaccine. 2026;82:128582.
    PubMed         Abstract available
    
    
39. RICE E, Cheng AC, Britton PN, Carr J, et al
    Influenza epidemiology, treatment and prevention in Australian children: Trends from 6 years of PAEDS-FluCAN influenza surveillance (2019-2024).
    Vaccine. 2026;82:128592.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Influenza is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum